Loss of expression of the putative tumor suppressor NES1 gene in biopsy-proven ductal carcinoma in situ predicts for invasive carcinoma at definitive surgery

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial

Bernard Fisher, James J. Dignam, Norman Wolmark et al. · The Lancet · 1999 · 1K citations

Surgical Oncology, Breast Oncology, Medicine +10

Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853

Jean‐Pierre Julien, Nina Bijker, Ian S. Fentiman et al. · The Lancet · 2000 · 510 citations

Surgical Oncology, Radiation Therapy, Medicine +10

Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17

Edwin R. Fisher, James J. Dignam, Elizabeth Tan-Chiu et al. · Cancer · 1999 · 501 citations

[Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853].

G. Noël, Mazeron Jj · PubMed · 2001 · 459 citations

Radiation Medicine, Radiation Therapy, Medicine +10

The role for NES1 serine protease as a novel tumor suppressor.

Jaya Goyal, Karen Smith, John M. Cowan et al. · PubMed · 1998 · 169 citations

Cancer Res., Nes1 Gene, Novel Tumor Suppressor +11